Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2023

Gurska Lindsay M, Okabe Rachel, Schurer Alexandra, Tong Meng Maxine, Soto Mark, Choi Daniel, Ames Kristina, Glushakow-Smith Shira, Montoya Allison, Tein Ellen, Miles Linde A, Cheng Haiying, Hankey-Giblin Pamela, Levine Ross L, Goel Swati, Halmos Balazs, Gritsman Kira

Abstract excerpt

PURPOSE: The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are characterized by JAK/STAT pathway activation. JAK inhibitors are approved for MPN treatment, but persistence has been observed, due to JAK/STAT reactivation. EXPERIMENTAL DESIGN: Using MPN patient samples, JAK2-mutated cell lines, and MPN mouse models, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Janus Kinases

Share to Lung Neoplasms

Share to Myeloproliferative Disorders

Share to Protein Kinase Inhibitors

Share to STAT Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 36537918
DOI: 10.1158/1078-0432.CCR-22-1763
PMCID: PMC9992133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.PMID 36537918Read ↗

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.Semantic proximity Read ↗

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNSemantic proximity Read ↗

JAK2 inhibition for the treatment of hematologic and solid malignanciesSemantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

A Hidden Driver Mutation in Myeloproliferative Neoplasms: SH2B3 and Diagnostic Implications and Response to Ropeginterferon Alfa-2b.Semantic proximity Read ↗

Jak2 <sup>V617F</sup> Reversible Activation Shows an Essential Requirement for Jak2 <sup>V617F</sup> in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.Semantic proximity Read ↗

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signalingSemantic proximity Read ↗

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read ↗

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Semantic proximity Read ↗

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.